ArticleRisk management and healthcare policy2026
Clinical Impact of Molecular Testing for Respiratory Viruses in Children Admitted with Acute Respiratory Diseases: Real-World Evidence.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To describe the impact of molecular testing for respiratory viruses (MTRV) integrated in an antimicrobial and diagnostic stewardship program analyzing antimicrobial prescription and length of stay (LOS) of children hospitalized with acute respiratory disease in a resource-limited setting. Methods: A retrospective case-control study was designed involving children hospitalized with acute respiratory disease. Interventions in the case group included implementation of MTRV in a 24 h clinical microbiology service, results available during the first day of hospitalization, training technicians and medical staff in sampling, results interpretation, supervisions and recommendation about antibiotic prescriptions by pediatric infectious diseases and pneumologist. Main outcomes were mean LOS, antibiotic prescriptions and days of therapy (DOT). Results: A total of 1200 children were included (396 cases and 804 controls), most of whom were younger than 5 years. Median LOS was shorter in the case group (5 vs 6 days; p≤0.05), with a 17.1% increase in hospitalizations lasting 1-4 days and a reduction in stays of 5-10 days (p<0.001). Antibiotic prescription was significantly lower in cases from day 1 (34.5% vs 81.0%; p<0.001) and remained lower on days 3 and 5. Viral detection on the first hospital day was associated with up to a 20% reduction in antibiotic use. We observed a reduction in DOTs/100 days for aminopenicillins with beta-lactamase inhibitors, third-generation cephalosporins, and macrolides (p<0.001). Viruses were detected in 66.4% of cases, mainly rhinovirus/enterovirus, RSV, SARS-CoV-2, and parainfluenza virus type 3. Conclusion: The integration of MTRV testing into a stewardship program reduced antibiotic use and shortened hospital stays in children with acute respiratory disease. Supporting the value of rapid molecular diagnostics as a key component of pediatric antimicrobial stewardship, especially in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.